NICE Explains Its UK Funding Recommendation For Kymriah
Executive Summary
The final appraisal document published today by the health technology assessment body NICE provides more insight into the health technology assessment body’s recent recommendation on
You may also be interested in...
Luxturna's EU Approval Highlights Gene Therapy Pricing Challenges
Novartis/Spark Therapeutics’ transformative gene therapy Luxturna has just been approved in the EU. Like other gene therapies, it comes with a heavy price tag. So how will Novartis convince payers to pay, and how will payers cope with expensive, game changing therapies in the future?
CAR-T Therapies Should Impress EU Reimbursement Bodies
Health authorities in Europe have different approaches to evaluating the cost-effectiveness of new drugs, but in the case of the CAR-T therapies, they are likely to look favorably on factors such as their innovative nature, the small patient populations, and the dearth of effective treatments.
CAR-T Funding: It's (Nearly) All About The Price In The UK
Gilead’s Yescarta and Novartis’s Kymriah are pioneering and effective approaches to the treatment of serious cancers, but in the UK they have had mixed fortunes at the hands of NICE, the body that decides whether new therapies are value for money and should be available under the national health service. Both companies will probably have to cut their asking price to secure routine funding